公司资料
ImmuCell 股价、新闻与催化剂
- 股票代码:
- ICCC
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
10.06 USD (-0.30%)
收盘价
最后更新: 2026年8月21日
88.6M USD
市值
股价为何变动
As of Aug 21, 2026, ICCC closed down 0.30% at $10.06. No new same-company headline was identified in the current news window.
公司概览
Animal Health Biologics Company
ImmuCell develops biologic products intended to improve calf health and productivity. The company primarily serves dairy and livestock markets, with an emphasis on preventing early-life diseases such as neonatal calf diarrhea.
First Defense Franchise
The First Defense product line orally delivers antibodies derived from colostrum to provide immediate immune protection against major viral and bacterial causes of calf scours. Dual-Force and Tri-Shield are the franchise’s key growth products.
Commercial Execution
Growth depends on product availability, U.S. market demand, expansion of the commercial team, and distributor inventory cycles. The release did not identify a specific future clinical or regulatory milestone.
未来催化剂
- ImmuCell’s catalysts are animal-health product demand, manufacturing execution, and steady recurring revenue in veterinary biologics. The company moves on operating consistency rather than binary headlines.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。